Share Buyback
EKF purchased 992,762 ordinary shares at 21.5p per share to be held in treasury.
- Ordinary Shares purchased 992,762
- Weighted average price paid 21.5p per share
- Total voting rights (post-purchase) 449,460,790
- Ordinary Shares held in treasury 5,469,774
Select text to share a quote on X · sign in to keep highlights & notes in your EKF notes
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that it has purchased a total of 992,762 of its ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a weighted average price of 21.5 pence per share. The Ordinary Shares purchased will be held in treasury.
Aggregated information
| Date of purchase | 8 May 2025 | ||
|---|---|---|---|
| Number of Ordinary Shares purchased | 992,762 | ||
| Highest price paid per Ordinary Share | 21.5p | ||
| Lowest price paid per Ordinary Share | 21.5p | ||
| Volume weighted average price paid | 21.5p | ||
| Transaction details | |||
| Number of Ordinary Shares purchased | Transaction price (GBp) | Time of transaction | Trading venue |
| 150,000 | 21.5p | 08:08:52 | AIMX |
| 550,000 | 21.5p | 09:41:34 | AIMX |
| 292,762 | 21.5p | 11:04:51 | AIMX |
Total voting rights
Following the purchase, the Company's total issued share capital will consist of 454,930,564 Ordinary Shares each carrying one voting right, of which 5,469,774 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 449,460,790. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
PDMR dealing
As part of the buyback and within the above aggregate purchase, EKF acquired 292,762 Ordinary Shares in total at a price of 21.5 pence per Ordinary Share from Harwood as investment manager to Oryx International Growth Fund Limited ("Oryx") and North Atlantic Smaller Companies Investment Trust PLC ("NASCIT"). EKF acquired 97,587 and 195,175 Ordinary Shares from Oryx and NASCIT respectively. Harwood has facilitated this transaction solely in order to ensure that the aggregate indirect beneficial interest of Mr. Mills remains at approximately the same level and in any event does not exceed 30% of the prevailing total voting rights in the Company following any repurchases.
Following the above sale of Ordinary Shares by Oryx and NASCIT to the Company, Mr. Mills' aggregate indirect interest in the Company is 132,541,418 Ordinary Shares.
Additional disclosures relating to this PDMR dealing are detailed below.
The person responsible for arranging the release of this Announcement
on behalf of the Company is Julian Baines, Executive Chair.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | |
| Julian Baines, Executive Chair | via Walbrook PR | |
| Gavin Jones, Chief Executive Officer | ||
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 | |
| Phil Davies / Oliver Platts | ||
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com | |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 | |
| a) | Name | Christopher Mills |
| 2 | Reason for the notification | |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | EKF Diagnostics Holdings plc |
| b) | LEI | 213800DXTF3EAUK1AR05 |
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 1 pence each |
| Identification code | GB0031509804 | |
| b) | Nature of the transaction | Disposal of Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| 21.5p | 292,762 | |
| d) | Aggregated information | |
| - Aggregated volume | n/a | |
| - Price | ||
| e) | Date of the transaction | 8 May 2025 |
| f) | Place of the transaction | London Stock Exchange, AIMX |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.